New mesothelioma drug turns cancer's own defenses against it

Scientists are testing a new experimental drug for mesothelioma, an aggressive asbestos-linked cancer with few effective treatments, which kills cancer cells by disabling PRX3, an antioxidant defense tumors use to survive intense oxidative stress. In an early clinical trial, it controlled disease progression in 67% of patients and produced encouraging survival results, raising hopes the strategy could eventually be used against other cancers.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.